|
1
|
Hillaert MA, Lentjes EG, Beygui F,
Kemperman H, Asselbergs FW, et al: Measuring and targeting
aldosterone and renin in atherosclerosis-a review of clinical data.
Am Heart J. 162:585–596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tomaschitz A, Pilz S, Ritz E, Meinitzer A,
Boehm BO and März W: Plasma aldosterone levels are associated with
increased cardiovascular mortality: the Ludwigshafen Risk and
Cardiovascular Health (LURIC) study. Eur Heart J. 31:1237–1247.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vantrimpont P, Rouleau JL, Ciampi A, et
al: Two-year time course and significance of neurohumoral
activation in the Survival and Ventricular Enlargement (SAVE)
Study. Eur Heart J. 19:1552–1563. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun Y, Zhang J, Lu L, Chen SS, Quinn MT
and Weber KT: Aldosterone-induced inflammation in the rat heart:
role of oxidative stress. Am J Pathol. 161:1773–1781. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pitt B, Bakris G, Ruilope LM, DiCarlo L
and Mukherjee R; EPHESUS Investigators: Serum potassium and
clinical outcomes in the Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
Circulation. 118:1643–1650. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Palmer BR, Pilbrow AP, Frampton CM, Yandle
TG, Skelton L, Nicholls MG and Richards AM: Plasma aldosterone
levels during hospitalization are predictive of survival
post-myocardial infarction. Eur Heart J. 29:2489–2496. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calhoun DA: Aldosterone and cardiovascular
disease: smoke and fire. Circulation. 114:2572–2574. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Keidar S, Kaplan M, Pavlotzky E, Coleman
R, Hayek T, Hamoud S and Aviram M: Aldosterone administration to
mice stimulates macrophage NADPH oxidase and increases
atherosclerosis development: a possible role for
angiotensin-converting enzyme and the receptors for angiotensin II
and aldosterone. Circulation. 109:2213–2220. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hatakeyama H, Miyamori I, Fujita T, Takeda
Y, Takeda R and Yamamoto H: Vasular aldosterone. Biosynthesis and a
link to angiotensin II-induced hypertrophy of vascular
smooth-muscle cells. J Biol Chem. 269:24316–24320. 1994.PubMed/NCBI
|
|
10
|
Godon C, Cordelières FP, Biard D, Giocanti
N, Méqnin-Chanet F, Hall J and Favaudon V: PARP inhibition versus
PARP-1 silencing: different outcomes in terms of single-strand
break repair and radiation susceptibility. Nucleic Acids Res.
36:4454–4464. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schultz N, Lopez E, Saleh-Gohari N and
Helleday T: Poly(ADP-ribose) polymerase (PARP-1) has a controlling
role in homologous recombination. Nucleic Acids Res. 31:4959–4964.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Claybon A, Karia B, Bruce C and Bishop AJ:
PARP1 suppresses homologous recombination events in mice in vivo.
Nucleic Acids Res. 38:7538–7545. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chiarugi A and Moskowitz MA: Cell biology.
PARP-1 – a perpetrator of apoptotic cell death? Science.
297:200–201. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rho YH, Chung CP, Oeser A, et al:
Inflammatory mediators and premature coronary atherosclerosis in
rheumatoid arthritis. Arthritis Rheum. 61:1580–1585. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pacher P and Szabó C: Role of
poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases:
the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev.
25:235–260. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii
T, Higaki J and Horiuchi M: Eplerenone with valsartan effectively
reduces atherosclerotic lesion by attenuation of oxidative stress
and inflammation. Arterioscler Thromb Vasc Biol. 26:917–921. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takai S, Jin D, Muramatsu M, Kirimura K,
Sakonjo H and Miyazaki M: Eplerenone inhibits atherosclerosis in
nonhuman primates. Hypertension. 46:1135–1139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pitt B, Remme W, Zannad F, et al:
Eplerenone, a selective aldosterone blocker, in patients with left
ventricular dysfunction after myocardial infarction. N Engl J Med.
348:1309–1321. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Diefenbach J and Bürkle A: Introduction to
poly(ADP-ribose) metabolism. Cell Mol Life Sci. 62:721–730. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsifetaki N, Georqiadis AN, Alamanos Y,
Fanis S, Arqyropoulou MI and Drosos AA: Subclinical atherosclerosis
in scleroderma patients. Scand J Rheumatol. 39:326–329. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jaffe EA, Nachman RL, Becker CG and Minick
CR: Culture of human endothelial cells derived from umbilical
veins. Identification by morphologic and immunologic criteria. J
Clin Invest. 52:2745–2756. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sand-Dejmek J, Adelmant G, Sobhian B,
Calkins AS, Marto J, Iqlehart DJ and Lazaro JB: Concordant and
opposite roles of DNA-PK and the “facilitator of chromatin
transcription” (FACT) in DNA repair, apoptosis and necrosis after
cisplatin. Mol Cancer. 10:742011. View Article : Google Scholar
|
|
23
|
Bryant HE, Schultz N, Thomas HD, et al:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haile WB, Echeverry R, Wu F, Guzman J, An
J, Wu J and Yepes M: Tumor necrosis factor-like weak inducer of
apoptosis and fibroblast growth factor-inducible 14 mediate
cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation
and neuronal death. Neuroscience. 171:1256–1264. 2010. View Article : Google Scholar : PubMed/NCBI
|
